BioInformant

Your Global Leader in Stem Cell Market Research

MENUMENU
  • Blog
  • Stem Cells
    • iPS Cells
    • MSCs
    • HSCs
    • Adipose SCs
    • Neural Stem Cells
  • Cell Therapy
    • COVID-19
    • CAR-T
    • Cord Blood
  • Exosomes
  • Interviews
  • News
    • Press Releases
    • Job Posts
  • Shop
    • Products
    • Submit PR
    • Advertise
  • About
    • Testimonials
    • Story
    • Guarantee
    • Contact
  • Home
  • Blog
    • Stem Cells
      • HSCs
      • iPS Cells
      • MSCs
      • Neural Stem Cells
      • Adipose SCs
    • Exosomes
    • Cell Therapy
      • CAR-T
    • Cord Blood
    • Stem Cell News
    • Interviews
  • COVID-19
  • Shop
  • Submit PR
  • Company
    • Advertise
    • Testimonials
    • Story
    • Job Posts
    • Guarantee
    • Privacy Policy
    • Contact
Home » Archives for Cade Hildreth (CEO)

About Cade Hildreth (CEO)

Cade Hildreth is the Founder of BioInformant.com, the world's largest publisher of stem cell industry news. Cade is a media expert on stem cells, recently interviewed by the Wall Street Journal, Los Angeles Business Journal, Xconomy, and Vogue Magazine. 

The Complete Guide To Virtual Stem Cell Conferences in 2021

January 22, 2021 By Cade Hildreth (CEO) Leave a Comment

Stem cell conferences

As the world has been rocked by the COVID-19 pandemic, most in-person conferences have been canceled or switched to online formats. This goes for stem cell conferences too. However, stem cell conferences are still happening in 2021, albeit mostly virtual.

Here is your complete guide to virtual stem cell conferences in 2021. Learn more below to decide which ones to attend. For ease of reference, they are organized by date. [Read more…]

Filed Under: Cell Therapy, Stem Cells

The New CO.DON Plant for the EU-approved Advanced Therapy Cartilage Regeneration Treatment Sets a Milestone in Cell Therapy for Commercial Manufacturing

January 22, 2021 By Cade Hildreth (CEO) Leave a Comment

CO.DON AG

Human cell experts from Germany’s  CO.DON AG are again cutting the edge: they have launched human cells production on an industrial scale! The demanding quality standards required of the manufacturing conditions for human cell transplants led to the development of Integrated Isolator Technology (IIT) alongside industrial partners, which went into operation at CO.DON´s Teltow site in 1999. [Read more…]

Filed Under: Cell Therapy

The Future of Stem Cell Therapeutics – Balancing Safety and Efficacy

January 20, 2021 By Cade Hildreth (CEO) 4 Comments

Safety Chart | The Future of Stem Cell Therapeutics – Balancing Safety and Efficacy

What do we know of the safety and efficacy of stem cell therapeutics? Over 50 years have passed since the discovery of hematopoietic stem cells (bone marrow transplantation to cure diseases such as leukemia), over 20 years since the discovery of human embryonic stem cells (hESC), and 15 years since the discovery of induced pluripotent stem cells (iPS cells). There are now thousands of stem cell trials underway in clinics worldwide.

Despite this experience, what do we actually know about the safety and efficacy of stem cell therapeutics? [Read more…]

Filed Under: HSCs, iPS Cells, MSCs, Neural Stem Cells, Stem Cells Tagged With: direct cell reprogramming, stem cell therapy

Results from phase 3 gene therapy trial for painful diabetic peripheral neuropathy has been published online by Clinical and Translational Science

January 20, 2021 By Cade Hildreth (CEO) Leave a Comment

Helixsmith phase 3 gene therapy
Results from the phase 3 gene therapy trial for painful diabetic peripheral neuropathy (DPN) have been published online by Clinical and Translational Science and suggest excellent safety profile and promising efficacy.

KEY POINTS

  • VM202 (donaperminogene seltoplasmid) is a first-in-class, proprietary, non-viral, potentially regenerative plasmid DNA gene therapy.

[Read more…]

Filed Under: Press Releases

JOP POST: Chief Manufacturing & Development Officer at Exopharm

January 17, 2021 By Cade Hildreth (CEO) Leave a Comment

Exopharm Logo

Job Title: Chief Manufacturing & Development Officer

Company: Exopharm

  • Exosome therapeutic bioproducts
  • World leader and innovator
  • Listed company based in Melbourne Australia
  • Lead the 20 person innovation and development team in this expanding biotech

Established in 2013 and listed in 2018, Exopharm (ASX:EX1) was founded on the conviction that exosomes/EVs will become a new class of medicines to treat a many medical conditions. [Read more…]

Filed Under: Exosomes, Job Posts

  • 1
  • 2
  • 3
  • …
  • 236
  • Next Page »

Let’s Get Social

  • Facebook
  • Twitter
  • Instagram
  • Pinterest
  • LinkedIn

Nanocellect

Marathon Products

Menu
  • Blog
  • Stem Cell News
    • Press Releases
  • Stem Cells
    • HSCs
    • iPS Cells
    • MSCs
    • Neural Stem Cells
    • Adipose SCs
  • Exosomes
  • Cell Therapy
    • CAR-T
  • Cord Blood
  • Interviews

Cart

Top Rated Products

  • US Cord Blood and Cord Tissue Storage Rates Rates of U.S. Cord Blood and Cord Tissue Storage - Historical and Projected
    Rated 0 out of 5
    $197
  • Job Posting on BioInformant Job Posting on BioInformant.com - Your Perfect Hire Is In Our Audience
    Rated 0 out of 5
    $297
  • BioInformant Audience Reach BioInformant's Audience with Your Press Announcement
    Rated 0 out of 5
    $397 $297
My Tweets

BioInformant's World-Class Clients

  • Submit Press Release
  • Advertise
  • Privacy and Terms

Copyright © 2021 · BIOINFORMANT, Your Global Leader in Stem Cell Market Research

| Email: [email protected] | Phone: 703-859-7617 |

800 Corporate Drive, Suite 301, Stafford, VA 22554, United States

Disclaimer: All statements made on this website are NOT expressed as medical claims or advice. They are not intended to diagnose, treat, cure or prevent any disease or condition. If you have a health condition or concern, consult your physician or health care provider.